Cocrystal Pharma (COCP) adds OPKO and insiders as major holders

Rhea-AI Filing Summary

OPKO Health, Inc. and affiliates reported large ownership stakes in Cocrystal Pharma, Inc. common stock. OPKO beneficially owns 5,692,916 shares, representing 29.6% of Cocrystal’s common stock based on 19,263,200 shares outstanding as of August 6, 2026. On July 31, 2026, OPKO entered a Securities Purchase Agreement to buy 5,474,053 shares for $5,000,000, at $0.9134 per share, using working capital.

Phillip Frost, M.D. reports beneficial ownership of 2,786,412 shares (including common shares, warrants, options and restricted stock units), or 13.9% of the class. Frost Gamma Investments Trust reports 2,712,977 shares, or 13.6%, and Steven D. Rubin reports 2,724,860 shares, or 14.1%. Recent activity includes OPKO’s private purchase and Frost Gamma’s open‑market purchases totaling 85,000 shares at weighted average prices between $0.87 and $0.9898 per share.

A Stockholders Rights Agreement provides voting agreements and irrevocable proxies in favor of designated individuals and grants OPKO and other parties a right of first refusal to participate in future equity financings until Cocrystal has raised $70 million in cumulative equity financings. The stakes are described as held for investment, while OPKO and its principals may adjust their positions over time.

Filing Explained

The August 7 Schedule 13D reports that OPKO Health completed its July 31 purchase from Cocrystal Pharma of 5,474,053 common shares for $5,000,000; because the shares came from the issuer, the transaction increases the share base and reduces existing holders’ percentage ownership absent offsetting changes.

Key Figures

OPKO beneficial ownership: 5,692,916 shares Shares outstanding: 19,263,200 shares OPKO investment size: $5,000,000 +5 more

8 metrics

OPKO beneficial ownership 5,692,916 shares Represents 29.6% of Cocrystal common stock as of August 6, 2026

Shares outstanding 19,263,200 shares Cocrystal common shares outstanding as of August 6, 2026

OPKO investment size $5,000,000 Total purchase price for 5,474,053 Cocrystal shares on July 31, 2026

OPKO purchase price $0.9134 per share Per-share price under the July 31, 2026 Securities Purchase Agreement

Phillip Frost beneficial holdings 2,786,412 shares Represents 13.9% of Cocrystal common stock including derivatives

Frost Gamma holdings 2,712,977 shares Represents 13.6% of Cocrystal common stock including warrant shares

Steven Rubin holdings 2,724,860 shares Represents 14.1% of Cocrystal common stock including options and RSUs

Equity financing threshold $70 million Cumulative equity financings before Stockholders Rights Agreement right of first refusal ends

Key Terms

Securities Purchase Agreement, Stockholders Rights Agreement, beneficial ownership, right of first refusal, +1 more

5 terms

Securities Purchase Agreement financial

"OPKO entered into a Securities Purchase Agreement with the Issuer"

A securities purchase agreement is a written contract between a buyer and a seller outlining the terms for buying or selling financial assets such as stocks or bonds. It specifies details like the price, quantity, and conditions of the transaction, similar to a shopping list with agreed-upon terms. For investors, it provides clarity and legal protection when transferring ownership of these financial instruments.

Stockholders Rights Agreement financial

"each of the Reporting Persons entered into a Stockholders Rights Agreement"

A stockholders rights agreement is a legal contract that spells out the specific rights and obligations of a company’s shareholders—such as voting power, limits on transferring shares, protections against dilution, dividend entitlements and procedures for selling or registering stock. For investors it matters because the agreement functions like a rulebook that determines how easy it is to influence management, sell holdings, or be diluted by new issuances, directly affecting control, liquidity and potential returns.

beneficial ownership financial

"OPKO disclaims beneficial ownership of the securities of the Issuer"

Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.

right of first refusal financial

"the Issuer granted the Reporting Persons ... a right of first refusal"

A right of first refusal gives an existing shareholder or party the chance to buy an asset or shares before the owner can sell them to someone else. Think of it like being offered the first option to buy a house when the owner decides to sell; it matters to investors because it can limit who can acquire a stake, slow or block transactions, and affect the price and liquidity of an investment by restricting open-market sales or new buyers.

irrevocable proxy financial

"entered into voting agreements and granted an irrevocable proxy"

An irrevocable proxy is a legal authorization in which a shareholder gives another person or entity the permanent right to vote their shares and cannot later take that voting permission back. It matters to investors because it locks who controls voting power on key issues—like board elections, mergers, or major policy changes—so it can change corporate control and influence the value or direction of an investment much like handing someone an unchangeable voting card.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/07/2026 - 07:50 PM Accepted by SEC EDGAR 08/07/2026 - 07:49 PM Learn about SEC filing dates

FAQ

How many Cocrystal Pharma (COCP) shares does OPKO Health now beneficially own?

OPKO Health beneficially owns 5,692,916 Cocrystal Pharma common shares, representing 29.6% of the class, based on 19,263,200 shares outstanding as of August 6, 2026, as communicated by Cocrystal to the reporting persons.

What investment did OPKO Health make in Cocrystal Pharma (COCP) on July 31, 2026?

On July 31, 2026, OPKO purchased 5,474,053 Cocrystal shares for a total of $5,000,000 at $0.9134 per share under a Securities Purchase Agreement, using working capital as the source of funds.

What are Phillip Frost’s beneficial ownership and percentage in Cocrystal Pharma (COCP)?

Phillip Frost reports beneficial ownership of 2,786,412 Cocrystal shares, or 13.9% of the common stock. This includes common shares, warrants, stock options exercisable within 60 days, and restricted stock units vesting within 60 days.

What right of first refusal do OPKO and affiliates have in Cocrystal Pharma (COCP)?

Under a Stockholders Rights Agreement, OPKO and certain other parties have a right of first refusal to participate in future equity financings until Cocrystal has cumulatively raised $70 million in equity financings.

What recent open-market purchases did Frost Gamma make in Cocrystal Pharma (COCP)?

Within 60 days of the filing, Frost Gamma Investments Trust bought 85,000 Cocrystal shares in the open market for about $80,404.18, at weighted average prices of $0.9412 and $0.9816 per share on August 3 and August 5, 2026.

What are Steven D. Rubin’s reported holdings in Cocrystal Pharma (COCP)?

Steven D. Rubin reports beneficial ownership of 2,724,860 Cocrystal shares, representing 14.1% of the common stock. This includes common shares, options exercisable within 60 days, and restricted stock units scheduled to vest within 60 days.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13D

Under the Securities Exchange Act of 1934

Cocrystal Pharma, Inc.

(Name of Issuer)

Common Stock, par value $0.001 per share

(Title of Class of Securities)

19188J409

(CUSIP Number)

Camielle Green
OPKO Health, Inc., 4400 Biscayne Blvd.
Miami, FL, 33137
3055754100

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

07/31/2026

(Date of Event Which Requires Filing of This Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

schemaVersion:

SCHEDULE 13D

CUSIP Number(s): 19188J409

1

Name of reporting person

OPKO HEALTH, INC.

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

WC

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 5,692,916.00
8	Shared Voting Power 0.00
9	Sole Dispositive Power 5,692,916.00
10	Shared Dispositive Power 0.00

11

Aggregate amount beneficially owned by each reporting person

5,692,916.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

29.6 %

14

Type of Reporting Person (See Instructions)

CO

Comment for Type of Reporting Person:

(1) The percentage provided in Item 13 is calculated based on 19,263,200 shares outstanding as of August 6, 2026, as communicated by the Issuer to the Reporting Person.

SCHEDULE 13D

CUSIP Number(s): 19188J409

1

Name of reporting person

FROST PHILLIP MD ET AL

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

OO

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 2,786,412.00
8	Shared Voting Power 0.00
9	Sole Dispositive Power 2,786,412.00
10	Shared Dispositive Power 0.00

11

Aggregate amount beneficially owned by each reporting person

2,786,412.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

13.9 %

14

Type of Reporting Person (See Instructions)

IN

Comment for Type of Reporting Person:

(1) The amounts provided in Items 7, 9, and 11 include (i) 1,993,551 shares of Common Stock held by Frost Gamma Investments Trust ("FGIT"), which is controlled by Dr. Frost as sole trustee; (ii) 719,425 shares of Common Stock issuable upon exercise of warrants held by FGIT, which are exercisable within 60 days; (iii) 20,325 shares of Common Stock held by Dr. Frost, options to acquire 51,417 shares of Common Stock, which are exercisable within 60 days; and (iv) 1,693 shares of Common Stock issuable upon the vesting of restricted stock units within 60 days. (2) The percentage provided in Item 13 is calculated based on (i) 19,263,200 shares outstanding as of August 6, 2026, as communicated by the Issuer to the Reporting Person; (ii) 719,425 shares of Common Stock issuable upon exercise of warrants, which are exercisable within 60 days; (iii) options to acquire 51,417 share of Common Stock, which are exercisable within 60 days; and (iv) 1,693 shares of Common Stock issuable upon the vesting of restricted stock units within 60 days.

SCHEDULE 13D

CUSIP Number(s): 19188J409

1

Name of reporting person

Frost Gamma Investments Trust

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

OO

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

FLORIDA

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 2,712,977.00
8	Shared Voting Power 0.00
9	Sole Dispositive Power 2,712,977.00
10	Shared Dispositive Power 0.00

11

Aggregate amount beneficially owned by each reporting person

2,712,977.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

13.6 %

14

Type of Reporting Person (See Instructions)

OO

Comment for Type of Reporting Person:

(1) The amounts provided in Items 7, 9, and 11 include (i) 1,993,551 shares of Common Stock; and (ii) 719,425 shares of Common Stock issuable upon exercise of warrants, which are exercisable within 60 days. (2) The percentage provided in Item 13 is calculated based on (i) 19,263,200 shares outstanding as of August 6, 2026, as communicated by the Issuer to the Reporting Person; and (ii) 719,425 shares of Common Stock issuable upon exercise of warrants, which are exercisable within 60 days.

SCHEDULE 13D

CUSIP Number(s): 19188J409

1

Name of reporting person

Rubin Steven D

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

OO

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 2,724,860.00
8	Shared Voting Power 0.00
9	Sole Dispositive Power 2,724,860.00
10	Shared Dispositive Power 0.00

11

Aggregate amount beneficially owned by each reporting person

2,724,860.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

14.1 %

14

Type of Reporting Person (See Instructions)

IN

Comment for Type of Reporting Person:

(1) The amounts provided in Items 7, 9, and 11 include (i) 2,660,242 shares of Common Stock; (ii) options to acquire 50,402 shares of Common Stock, which are exercisable within 60 days; and (iii) 14,217 shares of Common Stock issuable upon the vesting of restricted stock units within 60 days. (2) The percentage provided in Item 13 is calculated based on (i) 19,263,200 shares outstanding as of August 6, 2026, as communicated by the Issuer to the Reporting Person; (ii) options to acquire 50,401 shares of Common Stock, which are exercisable within 60 days; and (iii) 14,217 shares of Common Stock issuable upon the vesting of restricted stock units within 60 days.

SCHEDULE 13D

Item 1.	Security and Issuer
(a)	Title of Class of Securities: Common Stock, par value $0.001 per share
(b)	Name of Issuer: Cocrystal Pharma, Inc.
(c)	Address of Issuer's Principal Executive Offices: 19805 N. CREEK PARKWAY, BOTHELL, WASHINGTON , 98011.
Item 2.	Identity and Background
(a)	This statement is being filed by: (i) OPKO Health, Inc. ("OPKO"), a corporation incorporated under the laws of the State of Delaware; (ii) Phillip Frost, M.D. as Chief Executive Officer of OPKO ("Dr. Frost"); (iii) Frost Gamma Investments Trust ("FGIT"), a trust organized under the laws of the State of Florida; and (iv) Steven D. Rubin ("Mr. Rubin"). Each of the foregoing is referred to as a "Reporting Person" and collectively as the "Reporting Persons". The Reporting Persons have entered into a joint filing agreement, dated as of August 7, 2026, a copy of which is attached hereto as Exhibit 2.
(b)	The address of the principal business and principal office of OPKO is 4400 Biscayne Blvd., Miami, Florida 33137. The address of the principal business and principal office of Dr. Frost, FGIT and Mr. Rubin is 4400 Biscayne Blvd., Suite 1500, Miami, Florida 33137.
(c)	OPKO is a diversified healthcare company that seeks to establish industry-leading positions in large and rapidly growing medical markets. Dr. Frost's principal occupation is serving as Chairman and Chief Executive Officer of OPKO. The principal business of FGIT is to invest in securities. Dr. Frost is the sole trustee of FGIT. Mr. Rubin's principal occupation is serving as Executive Vice President - Administration and Director of OPKO.
(d)	No Reporting Person or any of the persons listed on Exhibit 1 hereto has, during the last five years, been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors).
(e)	No Reporting Person has, during the last five years, been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violations with respect to such laws.
(f)	Dr. Frost and Mr. Rubin are citizens of the United States of America. OPKO was incorporated in the State of Delaware. FGIT was organized in the State of Florida.
Item 3.	Source and Amount of Funds or Other Consideration
	OPKO entered into a Securities Purchase Agreement with the Issuer pursuant to which OPKO purchased 5,474,053 shares of Common Stock for a total purchase price of $5,000,000. The source of funds used by OPKO for its acquisition of securities of the Issuer was working capital. For information with respect to Dr. Frost and FGIT, please refer to the Schedule 13D/A filed on August 7, 2026, which is incorporated by reference herein.
Item 4.	Purpose of Transaction
	OPKO acquired the shares of Common Stock for investment purposes. On July 31, 2026, OPKO and Issuer entered into the Securities Purchase Agreement pursuant to which OPKO purchased $5,000,000 of Common Stock from the Issuer. Dr. Frost and FGIT acquire shares of common stock for investment purposes. Further, in their capacity as directors of the Issuer, Dr. Frost and Mr. Rubin may, from time to time, formulate plans or proposals regarding the Issuer or its securities for consideration by the board of directors of the Issuer and the Issuer's management. OPKO intends to review its investments in the Issuer on a continuing basis. Depending on various factors, including, without limitation, the Issuer's financial position and strategic direction, actions taken by the board of directors, price levels of shares of the Common Stock, other investment opportunities available to OPKO, concentration of positions in the portfolios managed by OPKO, market conditions and general economic and industry conditions, OPKO may in the future take such actions with respect to their investments in the Issuer as it deems appropriate, including, without limitation, purchasing additional shares of the Common Stock or other financial instruments related to the Issuer or selling some or all of their beneficial or economic holdings, engaging in hedging or similar transactions with respect to the securities relating to the Issuer and/or otherwise changing their intention with respect to any and all matters referred to in Item 4 of Schedule 13D. In connection with a transaction and series of related mergers (collectively, the "Merger") through which Cocrystal Merger Sub, Inc., a Delaware corporation, and RFS Pharma, LLC, a Georgia limited liability company ("RFS Pharma"), became wholly-owned subsidiaries of the Issuer, each of the Reporting Persons entered into a Stockholders Rights Agreement with the Issuer and certain other persons (the "Stockholders Rights Agreement"). Under the Stockholders Rights Agreement, each of the Reporting Persons and other parties thereto (other than the Issuer) entered into voting agreements and granted an irrevocable proxy with respect to the voting of Common Stock and any preferred stock of the Issuer in favor of certain individuals selected in accordance with the Stockholders Rights Agreement. Additionally, the Issuer granted the Reporting Persons and other parties to the Stockholders Rights Agreement a right of first refusal on participation in future equity financings by the Issuer until such time as the Issuer has cumulatively raised $70 million in equity financings. Dr. Frost and Mr. Rubin currently serve as directors of the Issuer. This filing shall not be deemed an admission that any of the Reporting Persons constituted a "group" with any other signatories of the Stockholders Rights Agreement for purposes of Section 13(d) of the Exchange Act. Except as disclosed herein, none of the Reporting Persons has any plans or proposals which relate to or which would result in any of the actions specified in this paragraph of Item 4 of Schedule 13D.
Item 5.	Interest in Securities of the Issuer
(a)	The information contained in rows 7, 8, 9, 10, 11 and 13 on each of the cover pages of this Schedule 13D and the information set forth or incorporated in Items 2, 3, 4 and 6 is incorporated by reference in its entirety into this Item 5. OPKO's reported ownership does not include securities beneficially owned by FGIT, Dr. Frost or Mr. Rubin. OPKO disclaims beneficial ownership of the securities of the Issuer owned by FGIT, Dr. Frost, and Mr. Rubin. Dr. Frost and FGIT's reported ownership does not include securities owned by OPKO. In addition to serving as Chairman and Chief Executive Officer of OPKO, Dr. Frost and entities controlled by Dr. Frost (including FGIT) beneficially own approximately 34% of the outstanding common stock of OPKO. Dr. Frost and FGIT each disclaim beneficial ownership of the securities of the Issuer owned by OPKO. Richard C. Pfenniger, Jr., a member of the board of directors of the Issuer and OPKO beneficially owns 87,551, or approximately 0.45% of the outstanding shares of Common Stock, which include shares of Common Stock issuable upon the exercise of stock options, warrants, and restricted stock units, exercisable within 60 days. Mr. Pfenniger has no voting or other rights and no beneficial interest in the shares of Common Stock owned by each of OPKO, Dr. Frost and FGIT. This report shall not be deemed an admission that Mr. Pfenniger is the beneficial owner of the securities for any purpose.
(b)	The information contained in rows 7, 8, 9, 10, 11 and 13 on each of the cover pages of this Schedule 13D and the information set forth or incorporated in Items 2, 3, 4 and 6 is incorporated by reference in its entirety into this Item 5. OPKO's reported ownership does not include securities beneficially owned by FGIT, Dr. Frost or Mr. Rubin. OPKO disclaims beneficial ownership of the securities of the Issuer owned by FGIT, Dr. Frost, and Mr. Rubin. Dr. Frost and FGIT's reported ownership does not include securities owned by OPKO. In addition to serving as Chairman and Chief Executive Officer of OPKO, Dr. Frost and entities controlled by Dr. Frost (including FGIT) beneficially own approximately 34% of the outstanding common stock of OPKO. Dr. Frost and FGIT each disclaim beneficial ownership of the securities of the Issuer owned by OPKO. Richard C. Pfenniger, Jr., a member of the board of directors of the Issuer and OPKO beneficially owns 87,551, or approximately 0.45% of the outstanding shares of Common Stock, which include shares of Common Stock issuable upon the exercise of stock options, warrants, and restricted stock units, exercisable within 60 days. Mr. Pfenniger has no voting or other rights and no beneficial interest in the shares of Common Stock owned by each of OPKO, Dr. Frost and FGIT. This report shall not be deemed an admission that Mr. Pfenniger is the beneficial owner of the securities for any purpose.
(c)	In the last 60 days prior to the filing of this Schedule 13D, Mr. Rubin has not effected any transactions in the shares of Common Stock. In the last 60 days prior to the filing of this Schedule 13D, OPKO acquired a total of 5,474,053 shares of Common Stock on July 31, 2026, pursuant to the Securities Purchase Agreement for a per share purchase price of $0.9134 and a total purchase price of $5,000,000. In the last 60 days prior to the filing of this Schedule 13D, FGIT acquired a total of 85,000 shares of Common Stock on the open market at prices ranging from $0.87 to $0.9898 per share for an aggregate purchase price of approximately $80,404.18 as set forth below: Date: August 3, 2026 Shares: 75,000 Aggregate Purchase Price: $70,587.84 Weighted Average Price Per Share: $0.9412 Date: August 5, 2026 Shares: 10,000 Aggregate Purchase Price: $9,816.34 Weighted Average Price Per Share: $0.9816 In addition, on June 30, 2026, Dr. Frost and Mr. Rubin acquired shares of Common Stock as the result of the vesting of restricted stock units in the amounts of 1,694 shares and 504 shares, respectively.
(d)	No other person is known to the Reporting Persons to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the shares of the Common Stock covered by this Schedule 13D.
(e)	Not applicable.
Item 6.	Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer
	The information set forth or incorporated in Item 4 is incorporated by reference in its entirety into this Item 6. On August 7, 2026, the Reporting Persons entered into a Joint Filing Agreement in which the Reporting Persons agreed to the joint filing on behalf of each of them of statements on Schedule 13D with respect to the securities of the Issuer to the extent required by applicable law. The Joint Filing Agreement is attached hereto as Exhibit 2 and is incorporated by reference. Except for the matters described herein, the Reporting Persons do not have any contract, arrangement, understanding or relationship (legal or otherwise) with any person with respect to the securities of the Issuer.
Item 7.	Material to be Filed as Exhibits.
	Exhibit 1 OPKO Directors and Executive Officers Exhibit 2 Joint Filing Agreement Exhibit 3 Stockholder Rights Agreement, dated as of November 25, 2014 (2) Exhibit 4 Power of Attorney (2) Incorporated by reference to Exhibit 4.1 of the Issuer's Form 8-K filed with the Securities and Exchange Commission on December 1, 2014.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

OPKO HEALTH, INC.

Signature:	/s/ Camielle Green
Name/Title:	Camielle Green, Associate General Counsel
Date:	08/07/2026

FROST PHILLIP MD ET AL

Signature:	/s/ Phillip Frost, M.D.
Name/Title:	Phillip Frost, M.D.
Date:	08/07/2026

Frost Gamma Investments Trust

Signature:	/s/ Phillip Frost, M.D.
Name/Title:	Phillip Frost, M.D., Trustee
Date:	08/07/2026

Rubin Steven D

Signature:	/s/ Steven D. Rubin
Name/Title:	Steven D. Rubin
Date:	08/07/2026